These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 20952100)

  • 21. Bivalirudin therapy is associated with improved clinical and economic outcomes in ST-elevation myocardial infarction patients undergoing percutaneous coronary intervention: results from an observational database.
    Pinto DS; Ogbonnaya A; Sherman SA; Tung P; Normand SL
    Circ Cardiovasc Qual Outcomes; 2012 Jan; 5(1):52-61. PubMed ID: 22235065
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
    White HD; Ohman EM; Lincoff AM; Bertrand ME; Colombo A; McLaurin BT; Cox DA; Pocock SJ; Ware JA; Manoukian SV; Lansky AJ; Mehran R; Moses JW; Stone GW
    J Am Coll Cardiol; 2008 Sep; 52(10):807-14. PubMed ID: 18755342
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation myocardial infarction: observations from the TIMI 8 trial. The Thrombolysis in Myocardial Infarction.
    Antman EM; McCabe CH; Braunwald E
    Am Heart J; 2002 Feb; 143(2):229-34. PubMed ID: 11835024
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic significance of elevated baseline troponin in patients with acute coronary syndromes and chronic kidney disease treated with different antithrombotic regimens: a substudy from the ACUITY trial.
    Acharji S; Baber U; Mehran R; Fahy M; Kirtane AJ; Lansky AJ; Stone GW
    Circ Cardiovasc Interv; 2012 Apr; 5(2):157-65. PubMed ID: 22354934
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bivalirudin for primary percutaneous coronary interventions: outcome assessment in the Ottawa STEMI registry.
    Hibbert B; MacDougall A; Labinaz M; O'Brien ER; So DY; Dick A; Glover C; Froeschl M; Marquis JF; Wells GA; Blondeau M; Le May MR
    Circ Cardiovasc Interv; 2012 Dec; 5(6):805-12. PubMed ID: 23149331
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic value of a high on-clopidogrel treatment platelet reactivity in bivalirudin versus abciximab treated non-ST-segment elevation myocardial infarction patients. ISAR-REACT 4 (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment-4) platelet substudy.
    Sibbing D; Bernlochner I; Schulz S; Massberg S; Schömig A; Mehilli J; Kastrati A
    J Am Coll Cardiol; 2012 Jul; 60(5):369-77. PubMed ID: 22682553
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial.
    Han Y; Guo J; Zheng Y; Zang H; Su X; Wang Y; Chen S; Jiang T; Yang P; Chen J; Jiang D; Jing Q; Liang Z; Liu H; Zhao X; Li J; Li Y; Xu B; Stone GW;
    JAMA; 2015 Apr; 313(13):1336-46. PubMed ID: 25775052
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduction in cardiac mortality with bivalirudin in patients with and without major bleeding: The HORIZONS-AMI trial (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction).
    Stone GW; Clayton T; Deliargyris EN; Prats J; Mehran R; Pocock SJ
    J Am Coll Cardiol; 2014 Jan 7-14; 63(1):15-20. PubMed ID: 24140664
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial.
    Gibson CM; Morrow DA; Murphy SA; Palabrica TM; Jennings LK; Stone PH; Lui HH; Bulle T; Lakkis N; Kovach R; Cohen DJ; Fish P; McCabe CH; Braunwald E;
    J Am Coll Cardiol; 2006 Jun; 47(12):2364-73. PubMed ID: 16781360
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trials.
    Mehran R; Pocock S; Nikolsky E; Dangas GD; Clayton T; Claessen BE; Caixeta A; Feit F; Manoukian SV; White H; Bertrand M; Ohman EM; Parise H; Lansky AJ; Lincoff AM; Stone GW
    JACC Cardiovasc Interv; 2011 Jun; 4(6):654-64. PubMed ID: 21700252
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic value of the SYNTAX score in patients with acute coronary syndromes undergoing percutaneous coronary intervention: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage StrategY) trial.
    Palmerini T; Genereux P; Caixeta A; Cristea E; Lansky A; Mehran R; Dangas G; Lazar D; Sanchez R; Fahy M; Xu K; Stone GW
    J Am Coll Cardiol; 2011 Jun; 57(24):2389-97. PubMed ID: 21658558
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention.
    Brener SJ; Moliterno DJ; Lincoff AM; Steinhubl SR; Wolski KE; Topol EJ
    Circulation; 2004 Aug; 110(8):994-8. PubMed ID: 15302778
    [TBL] [Abstract][Full Text] [Related]  

  • 33. One-year outcomes with abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary interventions in patients with non-ST-segment elevation myocardial infarction: updated results from the ISAR-REACT 4 trial.
    Schulz S; Kastrati A; Ferenc M; Massberg S; Birkmeier KA; Laugwitz KL; Kufner S; Gick M; Dommasch M; Schühlen H; Schömig A; Berger PB; Mehilli J; Neumann FJ;
    EuroIntervention; 2013 Aug; 9(4):430-6. PubMed ID: 23455033
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial.
    Stone GW; White HD; Ohman EM; Bertrand ME; Lincoff AM; McLaurin BT; Cox DA; Pocock SJ; Ware JH; Feit F; Colombo A; Manoukian SV; Lansky AJ; Mehran R; Moses JW;
    Lancet; 2007 Mar; 369(9565):907-19. PubMed ID: 17368152
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antithrombotic strategy in non-ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention: insights from the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry.
    Lopes RD; Peterson ED; Chen AY; Roe MT; Wang TY; Ohman EM; Magid DJ; Ho PM; Wiviott SD; Scirica BM; Alexander KP
    JACC Cardiovasc Interv; 2010 Jun; 3(6):669-77. PubMed ID: 20630461
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in high-risk patients undergoing percutaneous coronary intervention (from the Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty-Bivalirudin vs Heparin study).
    Patti G; Pasceri V; D'Antonio L; D'Ambrosio A; Macrì M; Dicuonzo G; Colonna G; Montinaro A; Di Sciascio G
    Am J Cardiol; 2012 Aug; 110(4):478-84. PubMed ID: 22583760
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bivalirudin: in patients with acute coronary syndromes : planned for urgent or early intervention.
    Deeks ED; Curran MP
    Drugs; 2008; 68(16):2345-56. PubMed ID: 18973397
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of Bivalirudin versus Bivalirudin plus glycoprotein IIb/IIIa inhibitor versus heparin plus glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes having percutaneous intervention for narrowed saphenous vein aorto-coronary grafts (the ACUITY trial investigators).
    Kumar D; Dangas G; Mehran R; Kirtane A; Bertrand M; Ebrahimi R; Guagliumi G; Brar S; Fahy M; Heller E; Moses J; Stone G
    Am J Cardiol; 2010 Oct; 106(7):941-5. PubMed ID: 20854954
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic value of angiographic lesion complexity in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the acute catheterization and urgent intervention triage strategy trial).
    Goto K; Lansky AJ; Ng VG; Pietras C; Nargileci E; Mehran R; Parise H; Feit F; Ohman EM; White HD; Bertrand ME; Desmet W; Hamon M; Stone GW
    Am J Cardiol; 2014 Dec; 114(11):1638-45. PubMed ID: 25312637
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of anticoagulant agents and risk of bleeding among patients admitted with myocardial infarction: a report from the NCDR ACTION Registry--GWTG (National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry--Get With the Guidelines).
    Kadakia MB; Desai NR; Alexander KP; Chen AY; Foody JM; Cannon CP; Wiviott SD; Scirica BM;
    JACC Cardiovasc Interv; 2010 Nov; 3(11):1166-77. PubMed ID: 21087753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.